Jose Ignacio Labarta Aizpún
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jose Ignacio Labarta Aizpún has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Koledova
Global Medical Affairs, Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany
4 shared publications - Antonio de Arriba Muñoz
Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain
2 shared publications Esteban Mayayo
Endocrinology Unit Department of Pediatrics Hospital Infantil Universitario “Miguel Servet” Zaragoza Spain
2 shared publications- Eva Barrio-Ollero
Departamento de Anatomía e Histología Humanas, Universidad de Zaragoza, Domingo Miral, 50009 Zaragoza, Spain
2 shared publications - Marta Ferrer Lozano
Pediatric Endocrinology Unit, Miguel Servet Children's University Hospital, Zaragoza, Spain
2 shared publications - Matthew Keiser
Ares Trading SA (an affiliate of Merck KGaA), Eysins, Switzerland
2 shared publications
Latest Publications
- Open Access
- 4 December 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1718161
Delphi-based Spanish consensus on the use of long-acting growth hormone in pediatric growth hormone deficiency: recommendations from the ConverGHe Working Group
Background: Long-acting growth hormone (LAGH) formulations have emerged as an alternative to daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency (GHD). Although evidence from meta-analyses and randomized trials supports their efficacy and safety, real-life data are still lacking, and therefore clinical guidance on their implementation remains limited. Objective: To develop expert-based recommendations for the clinical use of LAGH in pediatric GHD within Spain. Methods: A two-round Delphi approach was used. Based on a literature review, a scientific committee comprised of pediatric endocrinologists developed a questionnaire structured into three domains: (1) Main benefits of LAGH vs . daily rhGH; (2) Candidate profiles for LAGH therapy; and (3) Considerations for initiating LAGH and treatment monitoring. Panelists rated their level of agreement with each questionnaire statement on a 9-point Likert scale. Consensus was defined as ≥66.67% of responses on the same tertile as the median, labelled as disagreement on scores of 1–3, intermediate on scores of 4–6, and agreement on scores 7–9. Statements that did not reach consensus were reformulated and re-evaluated in round 2. Results: After two rounds, all statements achieved consensus on agreement. Specifically, consensus was reached on 92% of the statements in round 1 and three revised items related to insulin-like growth factor-1 (IGF-1), pharmacokinetics and dose adjustment criteria, as well as the use of LAGH in patients at risk of hypoglycemia, achieved consensus in round 2. The recommendations emphasize the similar efficacy and safety of LAGH compared to rhGH, raising its special interest in cases of poor adherence to daily formulations (e.g. adolescents, injection-related anxiety, multiple comorbid treatments or complex family circumstances), although LAGH should also be considered in other settings in a patient-centered approach. In addition, they provide guidance on key issues related to adequate dose initiation and titration, as well as therapeutic monitoring. Conclusion: This is the first Delphi consensus to provide national-level guidance on integrating LAGH into pediatric GHD care, offering practical recommendations based on current evidence and national expert opinion. Future long-term real-world experience will contribute to address questions regarding long-term efficacy and safety, and practice-related points such as indication and monitoring.
- 4 December 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1718161
Open AccessDelphi-based Spanish consensus on the use of long-acting growth hormone in pediatric growth hormone deficiency: recommendations from the ConverGHe Working Group
Background: Long-acting growth hormone (LAGH) formulations have emerged as an alternative to daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency (GHD). Although evidence from meta-analyses and randomized trials supports their efficacy and safety, real-life data are still lacking, and therefore clinical guidance on their implementation remains limited. Objective: To develop expert-based recommendations for the clinical use of LAGH in pediatric GHD within Spain. Methods: A two-round Delphi approach was used. Based on a literature review, a scientific committee comprised of pediatric endocrinologists developed a questionnaire structured into three domains: (1) Main benefits of LAGH vs . daily rhGH; (2) Candidate profiles for LAGH therapy; and (3) Considerations for initiating LAGH and treatment monitoring. Panelists rated their level of agreement with each questionnaire statement on a 9-point Likert scale. Consensus was defined as ≥66.67% of responses on the same tertile as the median, labelled as disagreement on scores of 1–3, intermediate on scores of 4–6, and agreement on scores 7–9. Statements that did not reach consensus were reformulated and re-evaluated in round 2. Results: After two rounds, all statements achieved consensus on agreement. Specifically, consensus was reached on 92% of the statements in round 1 and three revised items related to insulin-like growth factor-1 (IGF-1), pharmacokinetics and dose adjustment criteria, as well as the use of LAGH in patients at risk of hypoglycemia, achieved consensus in round 2. The recommendations emphasize the similar efficacy and safety of LAGH compared to rhGH, raising its special interest in cases of poor adherence to daily formulations (e.g. adolescents, injection-related anxiety, multiple comorbid treatments or complex family circumstances), although LAGH should also be considered in other settings in a patient-centered approach. In addition, they provide guidance on key issues related to adequate dose initiation and titration, as well as therapeutic monitoring. Conclusion: This is the first Delphi consensus to provide national-level guidance on integrating LAGH into pediatric GHD care, offering practical recommendations based on current evidence and national expert opinion. Future long-term real-world experience will contribute to address questions regarding long-term efficacy and safety, and practice-related points such as indication and monitoring.
- 30 June 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 249-271
Talla baja
La talla baja es un motivo frecuente de consulta. Las causas son múltiples, pero, en la mayoría de las ocasiones, se trata de variaciones normales del crecimiento y, muy pocas veces, se identifica una etiología responsable. El concepto de hipocrecimiento patológico incluye valorar no solamente la talla, sino también la velocidad de crecimiento, la talla genética y la estimación de la talla adulta. La talla baja idiopática es un concepto amplio y de difícil definición y, en los últimos años, se han identificado anomalías en genes implicados en el desarrollo del cartílago de crecimiento. El proceso diagnóstico debe ser escalonado y tiene por objetivo diferenciar una talla baja variante de la normalidad de una talla baja patológica, identificar la causa e instaurar un tratamiento lo antes posible. Una historia clínica y exploración completa, junto con una juiciosa valoración de la auxología, edad ósea y pruebas complementarias básicas, permiten orientar el diagnóstico sin necesidad de estudios avanzados. El tratamiento con hormona de crecimiento recombinante humana (rhGH) se debe realizar en las condiciones y dosis indicadas e iniciarlo lo antes posible durante la prepubertad. En esta revisión se realiza una actualización del tema, tanto a nivel del diagnóstico diferencial como de las posibilidades de tratamiento.
- 30 June 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 249-271
Talla baja
La talla baja es un motivo frecuente de consulta. Las causas son múltiples, pero, en la mayoría de las ocasiones, se trata de variaciones normales del crecimiento y, muy pocas veces, se identifica una etiología responsable. El concepto de hipocrecimiento patológico incluye valorar no solamente la talla, sino también la velocidad de crecimiento, la talla genética y la estimación de la talla adulta. La talla baja idiopática es un concepto amplio y de difícil definición y, en los últimos años, se han identificado anomalías en genes implicados en el desarrollo del cartílago de crecimiento. El proceso diagnóstico debe ser escalonado y tiene por objetivo diferenciar una talla baja variante de la normalidad de una talla baja patológica, identificar la causa e instaurar un tratamiento lo antes posible. Una historia clínica y exploración completa, junto con una juiciosa valoración de la auxología, edad ósea y pruebas complementarias básicas, permiten orientar el diagnóstico sin necesidad de estudios avanzados. El tratamiento con hormona de crecimiento recombinante humana (rhGH) se debe realizar en las condiciones y dosis indicadas e iniciarlo lo antes posible durante la prepubertad. En esta revisión se realiza una actualización del tema, tanto a nivel del diagnóstico diferencial como de las posibilidades de tratamiento.
- 30 June 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 249-271
Short stature
Short stature is a very common cause of referral. There are many causes of growth failure, but the great majority of cases are due to normal variants and only in a minority of cases an underlying disease is found. Pathological growth failure includes the consideration not only of short stature, but also growth velocity, genetic height and estimation of adult height. Idiopathic short stature is a broad concept difficult to define and in the last years new genes related to the development of the growth cartilage have been implicated. The diagnostic process should be stepwise and aims to differentiate between short stature that is a variant of normal and pathological short stature, identify the cause, and initiate treatment as soon as possible. A complete medical history and examination, together with a careful assessment of auxology, bone age, and basic complementary tests, allow the diagnosis to be guided without the need for advanced studies. Treatment with recombinant human growth hormone (rhGH) should be carried out under the indicated conditions and doses and started as soon as possible during prepuberty. This review presents the state of the art regarding differential diagnosis and therapeutic possibilities.
- 30 June 2025
- Published by Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria in Pediatría Integral
- p. 249-271
Short stature
Short stature is a very common cause of referral. There are many causes of growth failure, but the great majority of cases are due to normal variants and only in a minority of cases an underlying disease is found. Pathological growth failure includes the consideration not only of short stature, but also growth velocity, genetic height and estimation of adult height. Idiopathic short stature is a broad concept difficult to define and in the last years new genes related to the development of the growth cartilage have been implicated. The diagnostic process should be stepwise and aims to differentiate between short stature that is a variant of normal and pathological short stature, identify the cause, and initiate treatment as soon as possible. A complete medical history and examination, together with a careful assessment of auxology, bone age, and basic complementary tests, allow the diagnosis to be guided without the need for advanced studies. Treatment with recombinant human growth hormone (rhGH) should be carried out under the indicated conditions and doses and started as soon as possible during prepuberty. This review presents the state of the art regarding differential diagnosis and therapeutic possibilities.
- Open Access
- 1 March 2025
- Published by Asociacion Espanola de Psiquiatria del Nino y del Adolescente - Aepnya in Revista de Psiquiatría Infanto-Juvenil
- Vol. 42 (1) , 28-43
Salud mental infantojuvenil en atención primaria en tiempos de COVID: ¿qué ha cambiado?
Introducción: La pandemia por SARS-CoV-2 ha podido precipitar el deterioro de la Salud Mental Infantojuvenil (SMIJ), su manejo y tratamiento, por lo que este estudio trata de comparar el número de consultas relativas a la SMIJ atendidas en Atención Primaria (AP), así como la derivación a Atención Especializada (AE) y la prescripción farmacológica. Metodología: Estudio descriptivo y retrospectivo en pacientes pediátricos de AP en la provincia de Zaragoza por patología relacionada con la SMIJ en dos periodos: “prepandemia” y “pandemia”. Resultados: La muestra total fue de 6854 consultas (56,9% en "prepandemia" y 43,1% en "pandemia";p<0,001). En "pandemia" disminuyeron consultas por trastornos del sueño (N=541 vs N=420; p<0,001), enuresis (N=85 vs N=43; p<0,001), trastornos del comportamiento (N=918 vs N=671 ;p<0,001), trastorno del déficit de atención e hiperactividad (TDAH) (N=612 vs N=330;p<0,001) y alteraciones del desarrollo psicomotor (N=1004 vs N=765; p<0,001); se incrementaron las derivaciones a SMIJ por trastornos del sueño (N=34 vs N=138;p<0,001) y alteraciones del desarrollo psicomotor (N=52 vs N=236;p<0,001 con reducción de TDAH (N=198 vs N=81;p<0,001) y trastornos del comportamiento (N=580 vs N=233;p<0,001). La edad media de derivación fue inferior en "pandemia" (9,89 vs 7,64 años; p<0,001), con aumento de la ratio Psiquiatría/Psicología (de 5,2 a 5,9; p=0,018). Tras el subperiodo 2a se aumentó prescripción de psicofármacos del 2,6% al 4,4% (p<0,001). Conclusiones: Las consultas totales de SMIJ en AP han disminuido en "pandemia". Sin embargo, han cobrado mayor relevancia los trastornos del sueño y alteraciones del desarrollo psicomotor respecto a las consultas totales. Es posible que la telemedicina haya propiciado el sobretratamiento farmacológico y mayores tasas de derivación a SMIJ.
- 1 March 2025
- Published by Asociacion Espanola de Psiquiatria del Nino y del Adolescente - Aepnya in Revista de Psiquiatría Infanto-Juvenil
- Vol. 42 (1) , 28-43
Open AccessSalud mental infantojuvenil en atención primaria en tiempos de COVID: ¿qué ha cambiado?
Introducción: La pandemia por SARS-CoV-2 ha podido precipitar el deterioro de la Salud Mental Infantojuvenil (SMIJ), su manejo y tratamiento, por lo que este estudio trata de comparar el número de consultas relativas a la SMIJ atendidas en Atención Primaria (AP), así como la derivación a Atención Especializada (AE) y la prescripción farmacológica. Metodología: Estudio descriptivo y retrospectivo en pacientes pediátricos de AP en la provincia de Zaragoza por patología relacionada con la SMIJ en dos periodos: “prepandemia” y “pandemia”. Resultados: La muestra total fue de 6854 consultas (56,9% en "prepandemia" y 43,1% en "pandemia";p<0,001). En "pandemia" disminuyeron consultas por trastornos del sueño (N=541 vs N=420; p<0,001), enuresis (N=85 vs N=43; p<0,001), trastornos del comportamiento (N=918 vs N=671 ;p<0,001), trastorno del déficit de atención e hiperactividad (TDAH) (N=612 vs N=330;p<0,001) y alteraciones del desarrollo psicomotor (N=1004 vs N=765; p<0,001); se incrementaron las derivaciones a SMIJ por trastornos del sueño (N=34 vs N=138;p<0,001) y alteraciones del desarrollo psicomotor (N=52 vs N=236;p<0,001 con reducción de TDAH (N=198 vs N=81;p<0,001) y trastornos del comportamiento (N=580 vs N=233;p<0,001). La edad media de derivación fue inferior en "pandemia" (9,89 vs 7,64 años; p<0,001), con aumento de la ratio Psiquiatría/Psicología (de 5,2 a 5,9; p=0,018). Tras el subperiodo 2a se aumentó prescripción de psicofármacos del 2,6% al 4,4% (p<0,001). Conclusiones: Las consultas totales de SMIJ en AP han disminuido en "pandemia". Sin embargo, han cobrado mayor relevancia los trastornos del sueño y alteraciones del desarrollo psicomotor respecto a las consultas totales. Es posible que la telemedicina haya propiciado el sobretratamiento farmacológico y mayores tasas de derivación a SMIJ.
- 3 November 2023
- Published by Elsevier in Endocrine Practice
- Vol. 30 (1) , 57-63
Importance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy
- 3 November 2023
- Published by Elsevier in Endocrine Practice
- Vol. 30 (1) , 57-63
Importance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy
- Open Access
- 2 August 2023
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 10 (1) , e46893
Evaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions
Background: Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. Objective: This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. Methods: A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. Results: Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. Conclusions: This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.
- 2 August 2023
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 10 (1) , e46893
Open AccessEvaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions
Background: Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. Objective: This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. Methods: A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. Results: Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. Conclusions: This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.
- Open Access
- 1 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Evaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions (Preprint)
BACKGROUND Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. OBJECTIVE This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. METHODS A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. RESULTS Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. CONCLUSIONS This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.
- 1 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions (Preprint)
BACKGROUND Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. OBJECTIVE This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. METHODS A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. RESULTS Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. CONCLUSIONS This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.
- Open Access
- 30 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5808
Identification of miRNAs Involved in Foetal Growth Restriction Due to Maternal Smoking during Pregnancy
Introduction: Smoking during pregnancy is associated with reduced foetal growth, amongst other effects. Epigenetic modification in the foetus and placenta during embryonic development as a result of changes in the function of miRNAs is one of the pathophysiological mechanisms responsible for this. This dysregulation may be due to environmental changes or toxins such as tobacco. Objective: To study the impact of smoking during pregnancy and its role in intrauterine growth restriction via hypermethylated miRNAs. Materials and methods: The differences in methylation patterns for miRNAs in umbilical cord blood from low-birth-weight newborns of smoking mothers were compared with those from normal-weight newborns using MedIP-seq (StarArray). Results: Seven hypermethylated miRNAs were identified in the epigenetic study of cord blood from low-birth-weight newborns of smoking mothers in our sample. The miRNAs found to be hypermethylated were: MIR7-1, MIR3918, MIR1244-1, MIR4721, MIR25, MIR93, MIR3656. Conclusion: Intrauterine exposure to tobacco induces hypermethylation-mediated miRNA silencing in low-birth-weight newborns by modifying the expression of factors involved in vascular development, growth, and adaptation to hypoxia.
- 30 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5808
Open AccessIdentification of miRNAs Involved in Foetal Growth Restriction Due to Maternal Smoking during Pregnancy
Introduction: Smoking during pregnancy is associated with reduced foetal growth, amongst other effects. Epigenetic modification in the foetus and placenta during embryonic development as a result of changes in the function of miRNAs is one of the pathophysiological mechanisms responsible for this. This dysregulation may be due to environmental changes or toxins such as tobacco. Objective: To study the impact of smoking during pregnancy and its role in intrauterine growth restriction via hypermethylated miRNAs. Materials and methods: The differences in methylation patterns for miRNAs in umbilical cord blood from low-birth-weight newborns of smoking mothers were compared with those from normal-weight newborns using MedIP-seq (StarArray). Results: Seven hypermethylated miRNAs were identified in the epigenetic study of cord blood from low-birth-weight newborns of smoking mothers in our sample. The miRNAs found to be hypermethylated were: MIR7-1, MIR3918, MIR1244-1, MIR4721, MIR25, MIR93, MIR3656. Conclusion: Intrauterine exposure to tobacco induces hypermethylation-mediated miRNA silencing in low-birth-weight newborns by modifying the expression of factors involved in vascular development, growth, and adaptation to hypoxia.
- Open Access
- 17 November 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (4) , 887-897
Delphi consensus on the diagnosis and treatment of patients with short stature in Spain: GROW-SENS study
Purpose: To identify consensus aspects related to the diagnosis, monitoring, and treatment of short stature in children to promote excellence in clinical practice. Methods: Delphi consensus organised in three rounds completed by 36 paediatric endocrinologists. The questionnaire consisted of 26 topics grouped into: (1) diagnosis; (2) monitoring of the small-for-gestational-age (SGA) patient; (3) growth hormone treatment; and (4) treatment adherence. For each topic, different questions or statements were proposed. Results: After three rounds, consensus was reached on 16 of the 26 topics. The main agreements were: (1) diagnosis tests considered as a priority in Primary Care were complete blood count, biochemistry, thyroid profile, and coeliac disease screening. The genetic test with the greatest diagnostic value was karyotyping. The main criterion for initiating a diagnostic study was prediction of adult stature 2 standard deviations below the target height; (2) the main criterion for initiating treatment in SGA patients was the previous growth pattern and mean parental stature; (3) the main criterion for response to treatment was a significant increase in growth velocity and the most important parameter to monitor adverse events was carbohydrate metabolism; (4) the main attitude towards non-responding patients is to check their treatment adherence with recording devices. The most important criterion for choosing the delivery device was its technical characteristics. Conclusions: This study shows the different degrees of consensus among paediatric endocrinologists in Spain concerning the diagnosis and treatment of short stature, which enables the identification of research areas to optimise the management of such patients.
- 17 November 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (4) , 887-897
Open AccessDelphi consensus on the diagnosis and treatment of patients with short stature in Spain: GROW-SENS study
Purpose: To identify consensus aspects related to the diagnosis, monitoring, and treatment of short stature in children to promote excellence in clinical practice. Methods: Delphi consensus organised in three rounds completed by 36 paediatric endocrinologists. The questionnaire consisted of 26 topics grouped into: (1) diagnosis; (2) monitoring of the small-for-gestational-age (SGA) patient; (3) growth hormone treatment; and (4) treatment adherence. For each topic, different questions or statements were proposed. Results: After three rounds, consensus was reached on 16 of the 26 topics. The main agreements were: (1) diagnosis tests considered as a priority in Primary Care were complete blood count, biochemistry, thyroid profile, and coeliac disease screening. The genetic test with the greatest diagnostic value was karyotyping. The main criterion for initiating a diagnostic study was prediction of adult stature 2 standard deviations below the target height; (2) the main criterion for initiating treatment in SGA patients was the previous growth pattern and mean parental stature; (3) the main criterion for response to treatment was a significant increase in growth velocity and the most important parameter to monitor adverse events was carbohydrate metabolism; (4) the main attitude towards non-responding patients is to check their treatment adherence with recording devices. The most important criterion for choosing the delivery device was its technical characteristics. Conclusions: This study shows the different degrees of consensus among paediatric endocrinologists in Spain concerning the diagnosis and treatment of short stature, which enables the identification of research areas to optimise the management of such patients.
- Open Access
- 1 June 2021
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 13 (2) , 124-135
Important Tools for Use by Pediatric Endocrinologists in the Assessment of Short Stature
Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by use of novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature, and computer programs have improved ways in which diagnoses are coded for use by various groups such as healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to GH treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of IGF-I levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-I SDS is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of and keep abreast of these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at making clinical decisions more efficient and consider patient-centered approaches. Keywords: Short stature, height monitoring, bone age, cranial imaging, growth hormone treatment, prediction models.
- 1 June 2021
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 13 (2) , 124-135
Open AccessImportant Tools for Use by Pediatric Endocrinologists in the Assessment of Short Stature
Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by use of novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature, and computer programs have improved ways in which diagnoses are coded for use by various groups such as healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to GH treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of IGF-I levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-I SDS is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of and keep abreast of these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at making clinical decisions more efficient and consider patient-centered approaches. Keywords: Short stature, height monitoring, bone age, cranial imaging, growth hormone treatment, prediction models.